The global recombinant peptides market is expected to grow at a CAGR of 5.5% during the forecast period, to reach USD 3.2 billion by 2030. The growth of this market is driven by the increasing prevalence of chronic diseases such as diabetes and obesity, which are driving demand for recombinant peptides in insulin and human growth hormone applications.
Glucagon is one of the most commonly used recombinant peptides in insulin therapy, which has been used since the 1960s for treating severe hypoglycemia or diabetic emergencies. It stimulates release of glucose from liver glycogen stores and increases blood sugar levels in patients with low blood sugar levels due to diabetes or other conditions that cause hypoglycemia. Glucagon also helps maintain normal blood sugar levels after meals by stimulating release of insulin from pancreatic beta cells when glucose levels rise after eating a meal containing carbohydrates or protein.
Calcitonin is a hormone that regulates calcium metabolism and controls bone resorption (breakdown) by inhibiting osteoclasts (cells that break down bone). Calcitonin can be used to treat Paget's disease, hypercalcemia (high calcium level), osteoporosis, hyperparathyroidism (overactive parathyroid gland), and some types of cancer-related bone pain caused by metastases (cancer cells spreading from one part of the body to another).
Some Of The Growth Factors Of This Market:
- Increasing research and development activities in the field of biotechnology are also expected to fuel growth in this market over the forecast period.
- Technological advancements have led to an increase in production capacity for recombinant peptides, which has resulted in lower prices and increased accessibility for consumers worldwide, thereby fueling demand for these products over the forecast period.
Industry Growth Insights published a new data on “Recombinant Peptides Market”. The research report is titled “Recombinant Peptides Market research by Types (Glucagon, Calcitonin, Other), By Applications (Insulin, Human Growth Hormone, Blood Products, Other), By Players/Companies Sandoz Pharma, Stada Arzneimittel, Amgen, Hospira, Actavis, Cipla Ltd., Wockhardt Ltd., Biocon Ltd.”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant Peptides Market Research Report
By Type
Glucagon, Calcitonin, Other
By Application
Insulin, Human Growth Hormone, Blood Products, Other
By Companies
Sandoz Pharma, Stada Arzneimittel, Amgen, Hospira, Actavis, Cipla Ltd., Wockhardt Ltd., Biocon Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant Peptides Market Report Segments:
The global Recombinant Peptides market is segmented on the basis of:
Types
Glucagon, Calcitonin, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Insulin, Human Growth Hormone, Blood Products, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sandoz Pharma
- Stada Arzneimittel
- Amgen
- Hospira
- Actavis
- Cipla Ltd.
- Wockhardt Ltd.
- Biocon Ltd.
Highlights of The Recombinant Peptides Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Glucagon
- Calcitonin
- Other
- By Application:
- Insulin
- Human Growth Hormone
- Blood Products
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant Peptides Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Recombinant peptides are peptides that have been created by recombining two or more different proteins. This process allows for the creation of peptides with unique properties not possible when only one protein is used. Recombinant peptides can be used in a variety of research and therapeutic applications, including drug development and treatment.
Some of the major companies in the recombinant peptides market are Sandoz Pharma, Stada Arzneimittel, Amgen, Hospira, Actavis, Cipla Ltd., Wockhardt Ltd., Biocon Ltd..
The recombinant peptides market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Recombinant Peptides Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Recombinant Peptides Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Recombinant Peptides Market - Supply Chain
4.5. Global Recombinant Peptides Market Forecast
4.5.1. Recombinant Peptides Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Recombinant Peptides Market Size (000 Units) and Y-o-Y Growth
4.5.3. Recombinant Peptides Market Absolute $ Opportunity
5. Global Recombinant Peptides Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Recombinant Peptides Market Size and Volume Forecast by Type
5.3.1. Glucagon
5.3.2. Calcitonin
5.3.3. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Recombinant Peptides Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Recombinant Peptides Market Size and Volume Forecast by Application
6.3.1. Insulin
6.3.2. Human Growth Hormone
6.3.3. Blood Products
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Recombinant Peptides Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Recombinant Peptides Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Recombinant Peptides Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Recombinant Peptides Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Recombinant Peptides Demand Share Forecast, 2019-2026
9. North America Recombinant Peptides Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Recombinant Peptides Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Recombinant Peptides Market Size and Volume Forecast by Application
9.4.1. Insulin
9.4.2. Human Growth Hormone
9.4.3. Blood Products
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Recombinant Peptides Market Size and Volume Forecast by Type
9.7.1. Glucagon
9.7.2. Calcitonin
9.7.3. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Recombinant Peptides Demand Share Forecast, 2019-2026
10. Latin America Recombinant Peptides Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Recombinant Peptides Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Recombinant Peptides Market Size and Volume Forecast by Application
10.4.1. Insulin
10.4.2. Human Growth Hormone
10.4.3. Blood Products
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Recombinant Peptides Market Size and Volume Forecast by Type
10.7.1. Glucagon
10.7.2. Calcitonin
10.7.3. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Recombinant Peptides Demand Share Forecast, 2019-2026
11. Europe Recombinant Peptides Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Recombinant Peptides Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Recombinant Peptides Market Size and Volume Forecast by Application
11.4.1. Insulin
11.4.2. Human Growth Hormone
11.4.3. Blood Products
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Recombinant Peptides Market Size and Volume Forecast by Type
11.7.1. Glucagon
11.7.2. Calcitonin
11.7.3. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Yo-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Recombinant Peptides Demand Share, 2019-2026
12. Asia Pacific Recombinant Peptides Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Recombinant Peptides Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Recombinant Peptides Market Size and Volume Forecast by Application
12.4.1. Insulin
12.4.2. Human Growth Hormone
12.4.3. Blood Products
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Recombinant Peptides Market Size and Volume Forecast by Type
12.7.1. Glucagon
12.7.2. Calcitonin
12.7.3. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Recombinant Peptides Demand Share, 2019-2026
13. Middle East & Africa Recombinant Peptides Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Recombinant Peptides Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Recombinant Peptides Market Size and Volume Forecast by Application
13.4.1. Insulin
13.4.2. Human Growth Hormone
13.4.3. Blood Products
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Recombinant Peptides Market Size and Volume Forecast by Type
13.7.1. Glucagon
13.7.2. Calcitonin
13.7.3. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Recombinant Peptides Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Recombinant Peptides Market: Market Share Analysis
14.2. Recombinant Peptides Distributors and Customers
14.3. Recombinant Peptides Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Sandoz Pharma
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Stada Arzneimittel
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Amgen
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Hospira
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Actavis
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Cipla Ltd.
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Wockhardt Ltd.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Biocon Ltd.
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
